Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.49 |
| ▸ | NPY1R | P25929 | 6/20 | 0.49 |
| ▸ | NPY2R | P49146 | 4/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.49 |
| ▸ | FURIN | P09958 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506967 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL29536365 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL31198207 | 0.98 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL30466504 | 0.97 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL31276973 | 0.96 | FURIN (0.46) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL4537978 | 0.96 | FURIN (0.46) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL4537958 | 0.96 | FURIN (0.46) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL29850907 | 0.96 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RFURIN | |
| SCHEMBL29484773 | 0.95 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29789057 | 0.95 | NPY4R (0.50) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375146-A1 | Biologically Active Insulin Derivatives | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375146-A1 | Biologically Active Insulin Derivatives | IAPP, INSR, IGFBP1 | NPY4R 202/4885NPY1R 136/4885NPY2R 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.